| Quarterly Financials | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 58 | 34 | 30 | 20 | 21 | 18 | 13 | 15 | 27 | 19 | 8 | 8 |
| Expenses | 137 | 126 | 113 | 117 | 122 | 110 | 116 | 89 | 80 | 62 | 74 | 77 |
| EBITDA | -79 | -92 | -83 | -96 | -101 | -92 | -103 | -74 | -53 | -43 | -66 | -69 |
| Operating Profit % | -188 % | -427 % | -432 % | -740 % | -639 % | -555 % | -800 % | -494 % | -196 % | -540 % | -836 % | -817 % |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 | 9 |
| Profit Before Tax | -82 | -95 | -86 | -100 | -105 | -96 | -107 | -79 | -61 | -52 | -76 | -80 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 |
| Net Profit | -82 | -95 | -86 | -100 | -106 | -96 | -107 | -80 | -60 | -52 | -76 | -80 |
| EPS in ₹ | -2.55 | -2.94 | -2.66 | -3.07 | -3.26 | -2.96 | -3.31 | -2.45 | -1.84 | -1.60 | -2.34 | -2.48 |
Sun Pharma Advanced Research Co
Sun Pharma Advanced Research Co
144.50
-3.51
(-2.37%)
Market Cap
4,689.00 Cr
PE Ratio
-17.50
Volume
5,69,428.00
Day High - Low
148.45 - 144.03
52W High-Low
204.40 - 108.00
Key Fundamentals
Market Cap
4,689.00 Cr
EPS
-10.55
PE Ratio
-17.50
PB Ratio
-13.61
Book Value
-10.62
EBITDA
-321.30
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
157.88
Debt to Equity
0.00
Analyst Rating and Forecast
- By Refinitiv from2 analysts
Actual
Company News
View All News
Sun Pharmaceutical Industries Limited submitted its quarterly confirmation certificate under SEBI Depositories Regulations for Q4FY26, received from registrar MUFG Intime India.
Dr. Shravanti Bhowmik, Head of Operations Management at Sun Pharma Advanced Research Company Limited, resigned effective March 31, 2026, to join a group company opportunity.
Sun Pharma Advanced Research Company confirms compliance with SEBI disclosure regulations following BSE inquiry about increased trading volume on March 27, 2026.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,668.60 | #1 4,00,353.00 | 36.54 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 39.35 | |
6,280.00 | 1,66,714.30 | 67.27 | 9,712.00 | 18.67 | 2,191 | -1.02 | 60.00 | |
4,191.20 | 1,41,849.30 | 62.39 | 11,539.40 | 6.99 | 1,911 | 26.24 | 50.95 | |
2,328.70 | 1,06,431.70 | 22.80 | 22,909.50 | 13.74 | 3,306 | #1 37.44 | 55.39 | |
1,232.60 | 1,02,878.10 | #1 18.62 | 33,741.20 | 16.73 | 5,725 | -15.28 | 46.72 | |
1,229.50 | 99,316.60 | 21.90 | 28,409.50 | 7.12 | 5,291 | -57.18 | 43.64 | |
936.50 | 94,233.80 | 18.75 | 23,511.00 | 18.55 | 4,615 | -0.32 | 61.16 | |
2,144.00 | 88,505.40 | 49.08 | 12,744.20 | #1 20.90 | 2,007 | 7.65 | 59.05 | |
1,367.80 | 79,442.00 | 22.80 | 32,345.60 | 9.43 | 3,484 | 7.59 | 63.89 | |
5,642.00 | 67,458.60 | 27.81 | 13,458.30 | 3.70 | 2,216 | 1.90 | 61.46 |
Growth Rate
Revenue Growth
-29.90 %
Net Income Growth
-11.54 %
Cash Flow Change
16.05 %
ROE
-151.27 %
ROCE
-659.67 %
EBITDA Margin (Avg.)
23.12 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2023 | 2024 | 2025 |
| Total Assets | 830 | 515 | 336 |
| Fixed Assets | 106 | 108 | 99 |
| Current Assets | 455 | 269 | 26 |
| Capital Work in Progress | 27 | 44 | 54 |
| Investments | 291 | 2 | 0 |
| Other Assets | 407 | 362 | 183 |
| Total Equity & Liabilities | 830 | 515 | 336 |
| Current Liabilities | 179 | 265 | 374 |
| Non Current Liabilities | 138 | 124 | 178 |
| Total Equity | 513 | 126 | -217 |
| Reserve & Surplus | 480 | 93 | -249 |
| Share Capital | 33 | 33 | 33 |
Cash Flow
| Cash Flow | 2023 | 2024 | 2025 |
| Net Cash Flow | -1 | 5 | -3 |
| Investing Activities | -548 | 392 | 158 |
| Operating Activities | -69 | -429 | -360 |
| Financing Activities | 617 | 42 | 199 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 68.46 % | 68.46 % | 68.10 % | 68.10 % | 69.09 % | 69.09 % | 69.09 % | 68.22 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 3.30 % | 3.23 % | 2.64 % | 2.15 % | 2.23 % | 1.45 % | 1.47 % | 1.76 % | 2.04 % | 2.04 % |
| DIIs | 0.01 % | 0.02 % | 0.02 % | 0.02 % | 0.24 % | 0.24 % | 0.24 % | 0.93 % | 0.78 % | 0.78 % | 0.23 % | 0.81 % | 0.82 % | 0.18 % | 0.23 % | 0.64 % | 1.13 % | 0.97 % | 1.05 % | 0.78 % | 0.88 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 18.08 % | 18.00 % | 16.91 % | 16.94 % | 14.73 % | 16.45 % | 15.70 % | 16.00 % | 16.18 % | 16.13 % | 15.90 % | 16.09 % | 16.11 % | 18.91 % | 19.20 % | 18.89 % | 18.99 % | 19.15 % | 18.94 % | 19.20 % | 16.81 % |
| Others | 13.45 % | 13.52 % | 14.97 % | 14.94 % | 15.94 % | 14.22 % | 14.97 % | 14.85 % | 17.37 % | 17.42 % | 18.20 % | 14.13 % | 14.17 % | 12.60 % | 12.75 % | 12.58 % | 12.76 % | 12.73 % | 12.59 % | 12.30 % | 14.60 % |
| No of Share Holders | 0 | 99,454 | 1,10,301 | 94,834 | 95,039 | 93,097 | 94,494 | 93,718 | 96,337 | 1,00,807 | 1,01,433 | 1,03,990 | 1,02,743 | 1,25,184 | 1,28,205 | 1,31,034 | 1,42,864 | 1,40,724 | 1,36,997 | 1,44,810 | 1,40,625 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 12 Aug 2024 |  Annual General Meeting | NA | 12 Aug 2024 | 251.25 | 218.80 |
| 04 Nov 2024 |  Quarterly Result Announcement | NA | 04 Nov 2024 | 207.65 | 216.10 |
| 10 Feb 2025 | Quarterly Result Announcement | NA | 10 Feb 2025 | 157.60 | 158.85 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 140.85 | 161.20 |
| 04 Aug 2025 | Quarterly Result Announcement | NA | 04 Aug 2025 | 151.65 | 149.45 |
| 12 Aug 2025 | Annual General Meeting | NA | 12 Aug 2025 | 157.15 | 142.35 |
| 10 Nov 2025 | Quarterly Result Announcement | NA | 10 Nov 2025 | 137.05 | 133.30 |
| 09 Feb 2026 |  Extraordinary General Meeting | NA | 09 Feb 2026 | 135.45 | 139.05 |
| 09 Feb 2026 | Quarterly Result Announcement | NA | 09 Feb 2026 | 133.30 | 139.05 |
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Apr 06, 2026
Apr 06, 2026Announcement under Regulation 30 (LODR)-Change in ManagementApr 03, 2026
Apr 03, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMar 27, 2026
Mar 27, 2026Clarification Regarding Increase In VolumeMar 27, 2026
Mar 27, 2026Clarification sought from Sun Pharma Advanced Research Company LtdMar 27, 2026
Mar 27, 2026Closure of Trading WindowMar 26, 2026
Mar 26, 2026Addendum To The Valuation Report Issued On January 14 2026Feb 24, 2026
Feb 24, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 10, 2026
Feb 10, 2026Shareholder Meeting / Postal Ballot-Outcome of EGMFeb 09, 2026
Feb 09, 2026Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31 2025Feb 09, 2026
Feb 09, 2026Board Meeting Outcome for For Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025Feb 09, 2026
Feb 09, 2026Board Meeting Intimation for Approval Of Unaudited Financial Results For Quarter And Nine Months Ended December 31 2025Feb 03, 2026
Feb 03, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2026
Feb 03, 2026Clarification Regarding Increase In VolumeFeb 02, 2026
Feb 02, 2026Clarification sought from Sun Pharma Advanced Research Company LtdFeb 02, 2026
Feb 02, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 30, 2026
Jan 30, 2026Corrigendum To The Notice Of Extra Ordinary General Meeting Of The Company Scheduled To Be Held On Monday February 09 2026Jan 29, 2026
Jan 29, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 17, 2026
Jan 17, 2026Notice Of Extra Ordinary General Meeting Of Sun Pharma Advanced Research Company LimitedJan 16, 2026
Jan 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 16, 2026
Jan 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 15, 2026
Jan 15, 2026Board Meeting Outcome for Outcome Of The Board Meeting Held On January 14 2026Jan 14, 2026
Jan 14, 2026Announcement under Regulation 30 (LODR)-Investor PresentationJan 13, 2026
Jan 13, 2026Board Meeting Intimation for Approval Of Proposal For Raising Funds By The Company Through Preferential Issue Of Securities Including Convertible Warrants.Jan 11, 2026
Jan 11, 2026Announcement under Regulation 30 (LODR)-Investor PresentationJan 08, 2026
Jan 08, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2026
Jan 06, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 31, 2025
Dec 31, 2025Closure of Trading WindowDec 29, 2025
Dec 29, 2025Clarification Regarding Increase In The VolumeDec 03, 2025
Dec 03, 2025Clarification sought from Sun Pharma Advanced Research Company LtdDec 03, 2025
Dec 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 02, 2025
Dec 02, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 20, 2025
Nov 20, 2025Consolidation Of R&D Laboratories And FacilitiesNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2025
Nov 12, 2025Financial Results For The Quarter And Half-Year Ended September 30 2025Nov 10, 2025
Nov 10, 2025Board Meeting Outcome for Outcome Of The Board Meeting For Approval Of Unaudited Financial Results For The Quarter And Half Yearly Ended September 30 2025Nov 10, 2025
Nov 10, 2025Board Meeting Intimation for Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30 2025Oct 31, 2025
Oct 31, 2025Clarification Regarding Increase In The VolumeOct 29, 2025
Oct 29, 2025Clarification sought from Sun Pharma Advanced Research Company LtdOct 29, 2025
Oct 29, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Oct 09, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 05, 2025
Aug 05, 2025Unaudited Financial Results For The Quarter Ended June 30 2025Aug 04, 2025
Aug 04, 2025Board Meeting Outcome for Outcome Of The Board MeetingAug 04, 2025
Aug 04, 2025Board Meeting Intimation for Approval Of Unaudited Financial Statements For Quarter Ended June 30 2025Jul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 24, 2025
Jul 24, 2025Reg. 34 (1) Annual Report.Jul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2025
Jul 19, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 18, 2025
Jul 18, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Motilal Oswal BSE 1000 Index Fund Direct-Growth | 0.01% | 8 | 0.00% | 0.00% | |
 Angel One Nifty Total Market Index Fund Direct-Growth | 0.01% | 0 | 0.00% | 0.00% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.08% | 0 | 0.00% | -0.01% | |
Bandhan Nifty Total Market Index Fund Direct-Growth | 0.01% | 0 | 0.00% | 0.00% | |
 Groww Nifty Total Market Index Fund Direct-Growth | 0.01% | 0 | 0.00% | 0.00% | |
 HDFC BSE 500 Index Fund Direct-Growth | 0.00% | 0 | 0.00% | 0.00% | |
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth | 0.48% | 0 | 0.00% | 0.02% | |
 Mirae Asset Nifty Total Market Index Fund Direct-Growth | 0.01% | 0 | 0.00% | 0.00% | |
Motilal Oswal Nifty Microcap 250 Index Fund Direct-Growth | 0.16% | 0 | 0.00% | 0.00% |
Technical Indicators
RSI(14)
Neutral 59.08
ATR(14)
Less Volatile 9.29
STOCH(9,6)
Neutral 79.08
STOCH RSI(14)
Overbought 80.95
MACD(12,26)
Bullish 2.62
ADX(14)
Weak Trend 20.04
UO(9)
Bearish 56.12
ROC(12)
Uptrend And Accelerating 25.77
WillR(14)
Neutral -29.66
About Sun Pharma Advanced Research Co
Sun Pharma Advanced Research Company Ltd. (SPARC) is an India-based clinical-stage biopharmaceutical company focused on developing new drugs and delivery systems. It specializes in creating therapeutics in oncology, neurology, and immunology. SPARC's key projects include vodobatinib for chronic myelogenous leukemia and neurodegenerative diseases, an anti-MUC-1 antibody-drug conjugate for multiple cancers,...more
Website
Chairperson NameDilip S Shanghvi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
